(ARVN) Arvinas, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ARVN) Arvinas, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Arvinas, Inc. BCG Matrix is a company-specific strategic tool used to assess where its products or business units fit across Stars, Cash Cows, Question Marks, and Dogs. This page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
ARV-471 / vepdegestrant, Phase 3
ARV-471, now called vepdegestrant, is Arvinas’ lead Phase 3 asset in ER-positive/HER2-negative breast cancer, a group that makes up about 70% of breast cancer cases. The global breast cancer drug market was roughly $26 billion in 2025, so this is the company’s clearest Star if the trial data and launch path hold.
ARV-110 / bavdegalutamide, mCRPC
ARV-110, or bavdegalutamide, is an oral androgen receptor degrader for metastatic castration-resistant prostate cancer (mCRPC). mCRPC remains a high-need market, with about 35,000 U.S. cases a year and limited options after AR-pathway drugs. If efficacy and durability hold, it can become one of Arvinas, Inc.'s most visible value drivers.
ARV-766, next-gen AR degrader
ARV-766 is Arvinas’ next-generation androgen receptor degrader for prostate cancer, the same high-need market as ARV-110. It deepens the Company Name’s most advanced oncology franchise and gives the pipeline a second shot in a market with about 313,000 new prostate cancer cases and 35,000 deaths in the U.S. in 2025. In a BCG Matrix, it fits as a Star if data keep improving, since it targets a large, still-growing unmet-need space.
PROTAC oncology platform
Arvinas’ PROTAC oncology platform is a Star because targeted protein degradation keeps producing differentiated assets and partner pull. The company has 3 partnered oncology programs with Pfizer and Genentech, and its 2024 R&D spend was $324.2 million, showing continued reinvestment in the platform.
- Differentiate: targeted protein degradation
- Partnered oncology depth: 3 programs
- High reinvestment: $324.2 million R&D
- Platform still expanding in cancer
Pfizer partnership on vepdegestrant
Pfizer is Arvinas’ biggest strategic partner on vepdegestrant, Arvinas’ lead ER degrader. The deal gives Arvinas far wider clinical reach and a clearer path to commercialization, backed by Pfizer’s scale, which supports the asset’s best shot at a Star-like profile. The alliance was launched in 2021 with $650 million upfront and up to $1.4 billion in milestones.
- Largest partner on lead asset
- Expands trial and launch scale
- Best near-term Star catalyst
Arvinas’ Oncology Stars Shine on Vepdegestrant, ARV-110, and ARV-766
Arvinas, Inc.’s Star assets are vepdegestrant, bavdegalutamide, and ARV-766, all aimed at large oncology markets with clear unmet need. Vepdegestrant has the strongest near-term Star profile, backed by Pfizer and a $26 billion breast cancer drug market in 2025. ARV-110 and ARV-766 add depth in mCRPC, a high-need space with about 313,000 U.S. prostate cancer cases and 35,000 deaths in 2025.
| Asset | Star signal | Key data |
|---|---|---|
| Vepdegestrant | Lead Star | Phase 3, Pfizer deal |
| ARV-110 | Growth driver | mCRPC, 35,000 U.S. cases |
| ARV-766 | Pipeline Star | mCRPC, large unmet need |
What is included in the product
Detailed Word Document
Arvinas, Inc. BCG Matrix maps its pipeline and partnerships into invest, hold, or divest priorities.
Editable Excel File
Clean BCG matrix for Arvinas, Inc. to pinpoint growth bets and cut portfolio noise.
Reference Sources
Provides a credible source trail for Arvinas data, making claims easy to verify and decisions easier to defend.
Cash Cows
Pfizer collaboration funding
Pfizer collaboration funding is Arvinas, Inc.’s closest thing to recurring cash generation because it brings in partnership cash before any marketed product exists. The alliance helps pay for the company’s lead program and cuts Arvinas, Inc.’s own cash burn on the asset most likely to drive value. In BCG terms, that makes this a Cash Cow-like support stream: steady funding, low product risk, and direct relief for R&D spend.
Bayer AG alliance support
Arvinas, Inc.'s Bayer AG alliance is a cash cow-style support stream because it can bring non-dilutive funding and split development costs without needing product sales. That matters for a clinical-stage biotech: Arvinas reported no product revenue in its latest filings, so every partner dollar helps fund trials. Shared economics also reduce burn and extend runway.
Genentech / Roche alliance support
The Roche/Genentech tie-up gives Arvinas external validation for its targeted protein degradation platform, which matters in a high-risk R&D story. The alliance also brings collaboration cash that helps fund spending: Arvinas reported $1.0 billion+ in cash, cash equivalents, and marketable securities at FY2024 end, so this support reduces burn pressure. It reads more like operating support than product revenue, but it still improves runway and de-risks the platform.
Milestone-based revenue model
Arvinas, Inc. treats collaboration milestones as its cash cow: FY2024 revenue was still driven by partner payments, not drug sales, and cash, cash equivalents, and marketable securities were about $1.0 billion. That makes the inflow more stable than equity raises, but it still depends on deal progress, not steady product demand.
- Main mature inflow: partner milestones
- Less volatile than new share funding
- Still tied to collaboration execution
No marketed product revenue
Arvinas stayed a clinical-stage company through end-2025, so it had no marketed product revenue and no true Cash Cow in BCG terms. That means there was no steady, high-margin drug sales base to fund growth. In 2025, value creation still depended almost fully on pipeline execution, trial data, and future approvals.
- No approved drug, no product cash flow.
- Clinical-stage profile through end-2025.
- Pipeline execution drives all value.
Arvinas Has No Product Cash Cow—Only Partner-Funded R&D
Arvinas, Inc. has no marketed drug, so it has no true BCG Cash Cow from product sales in FY2025. The closest support is partner cash from Pfizer, Bayer AG, and Roche/Genentech, which helps fund R&D and cut burn. So the “cash cow” here is collaboration funding, not operations.
| Metric | FY2025 |
|---|---|
| Product revenue | $0 |
| Cash source | Partner funding |
| Business stage | Clinical-stage |
That means Arvinas, Inc. still depends on trial data and deal milestones, not steady sales.
Full Version Awaits
Arvinas, Inc. Reference Sources
The Arvinas, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No placeholders, no watermarks—just the full, professionally formatted report. It’s ready to download, review, and use for strategic analysis right away.
Dogs
0 approved products
Arvinas, Inc. had 0 approved commercial products at end-2025, so there is no low-growth legacy brand to classify as a true Dog in the BCG Matrix. The business was still almost entirely pipeline driven, with value tied to clinical progress rather than mature sales. In this setup, the “Dogs” bucket is effectively empty because the company has no marketed medicine to harvest or divest.
0 mature product franchises
Arvinas still has 0 approved, revenue-generating product franchises; product sales were $0, and the company leaned on collaboration revenue and R&D spending instead. With no long-lived brand or mature unit to harvest or divest, the Dogs bucket stays structurally near zero, so there is no entrenched market share to classify here.
No legacy revenue base
Arvinas, Inc. had no legacy product revenue base in FY2025, so there was nothing mature to defend in the matrix. Its income came mainly from collaboration revenue and financing, not from an old cash cow or a fading product line. That makes a classic low-share, low-growth "dog" harder to apply here.
No disclosed commercial divestiture asset
Arvinas has no disclosed marketed asset to divest, so this Dog is not a cash-trap product to prune. The portfolio is still in development, with value tied to pipeline readouts and not to maintaining a low-return commercial franchise. In FY2025, that means capital is still better pointed at R&D than at exit planning for a legacy asset.
- No marketed asset disclosed for sale
- Pipeline remains in development mode
- No obvious cash trap to prune
High burn, zero sales
Arvinas, Inc. has $0 product sales, so clinical development spend still drives cash burn. That makes the unit a funding drag in 2025, but not a true BCG Dog if the pipeline can still create future value. The issue is simple: no sales today, but high R&D keeps cash usage elevated.
- Zero sales, high burn
- R&D stays the main cost
- Value depends on pipeline readouts
Arvinas Has No BCG “Dog”—It’s a Pipeline Story, Not a Legacy Business
Arvinas, Inc. had $0 product sales in FY2025 and no approved commercial medicine, so there is no true Dog in the BCG Matrix to harvest or divest. The business was still pipeline-led, with value tied to clinical readouts, not a fading legacy franchise. Collaboration revenue, not product cash flow, supported the model.
| FY2025 item | Value |
|---|---|
| Product sales | $0 |
| Approved products | 0 |
| Dog bucket | Near zero |
Question Marks
ARV-471 / vepdegestrant, unapproved
ARV-471 (vepdegestrant) sits in a fast-growing breast cancer market, but it still has no approved sales and effectively 0% share, so it fits the Question Mark box. Arvinas and Pfizer reported Phase 3 VERITAC-2 data in ESR1-mutated ER+/HER2- metastatic breast cancer, a large late-line segment where CDK4/6-treated patients remain a key pool. Until FDA approval and launch, its value is all pipeline optionality, not market share.
ARV-110 / bavdegalutamide, unapproved
ARV-110 (bavdegalutamide) targets mCRPC, a large, high-need oncology market; the American Cancer Society projected about 313,780 new U.S. prostate cancer cases in 2025. Arvinas, Inc. has no product sales from this program yet, so it brings clinical upside but no revenue base. That makes it a clear Question Mark in the BCG Matrix.
ARV-766, unapproved
ARV-766 is an investigational androgen receptor degrader for prostate cancer, so it sits in Arvinas, Inc.'s Question Mark bucket: high-growth area, low proven adoption. Prostate cancer remains a large market, with about 1.47 million new cases globally in 2022, but ARV-766 still needs strong efficacy and safety data to win use.
Until later-stage results and clear approval data arrive, it has high upside but unclear share.
PROTAC discovery pipeline
Arvinas's PROTAC discovery pipeline sits in the Question Marks box: the company is still advancing several targeted protein degraders, but these assets remain early and unproven against standard care. That means high upside if one wins, but also high R&D cash use and clinical risk.
- Early-stage, low proof
- High capital burn
- Possible future growth driver
Future oncology expansion programs
Arvinas, Inc.'s future oncology expansion programs fit the Question Mark bucket: the company is pushing new indications and new degraders, but share is still unproven. In FY2024, Arvinas reported $63.4 million in total revenue and $478.9 million in cash, cash equivalents, and marketable securities, which supports pipeline growth but not clear market dominance yet.
That makes the next oncology launches high-upside, high-risk bets. Until newer degrader programs show clinical traction and commercial uptake, their market share stays unknown, so BCG logic still points to Question Marks.
- New indications can expand revenue.
- New degraders raise pipeline optionality.
- Market share remains unproven.
- Cash runway supports development, not certainty.
Arvinas’ pipeline bets still await a sales breakthrough
Arvinas, Inc.'s Question Marks are still pipeline bets: ARV-471, ARV-110, ARV-766, and newer degraders have high market potential but no approved sales, so share is near 0% until late-stage data turn into launches. In FY2024, revenue was $63.4 million and cash was $478.9 million, which funds R&D but does not prove demand.
| Asset | Status | BCG read |
|---|---|---|
| ARV-471 | Phase 3 | Question Mark |
| ARV-110 | Clinical | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.